Active Study Med for Schizophrenia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Maryland Psyciatric Research Center, Catonsville, MD
Schizophrenia+2 More
Prebiotic - DietarySupplement
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

The proposed project is based on the observation that schizophrenia is characterized by a chronic pro-inflammatory state, which contributes to the severity of a number of the clinical manifestations of the illness, including cognitive impairments, the treatment of which represents a critically important unmet therapeutic need.

Eligible Conditions

  • Schizophrenia
  • Schizoaffective Disorders

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Schizophrenia

Study Objectives

3 Primary · 5 Secondary · Reporting Duration: 12 weeks

12 weeks
Change in Affective Symptoms
Change in Negative Symptoms
Change in Positive Symptoms
Change in serum butyrate levels
Changes in Serum Measurements
Cognition
Effects of Gut Composition
Incidence of Side Effects

Trial Safety

Safety Progress

1 of 3

Other trials for Schizophrenia

Trial Design

2 Treatment Groups

Active Study Med
1 of 2
Placebo
1 of 2
Active Control
Non-Treatment Group

60 Total Participants · 2 Treatment Groups

Primary Treatment: Active Study Med · Has Placebo Group · N/A

Active Study Med
DietarySupplement
ActiveComparator Group · 1 Intervention: Prebiotic · Intervention Types: DietarySupplement
Placebo
DietarySupplement
PlaceboComparator Group · 1 Intervention: Placebo Prebiotic · Intervention Types: DietarySupplement

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks

Trial Background

Robert Buchanan, Chief, Maryland Psychiatric Research Center, Outpatient Research Program
Principal Investigator
University of Maryland, Baltimore
Closest Location: Maryland Psyciatric Research Center · Catonsville, MD
2019First Recorded Clinical Trial
3 TrialsResearching Schizophrenia
2 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are currently treated with an antipsychotic, with no dose changes in last 14 days.
You are able to understand the nature and risks of the study, and you are able to give informed consent.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.